GSK plc ADR Stock
Price
Target price
€36.00
€36.00
-0.550%
-0.2
-0.550%
€42.25
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
GSK plc ADR Stock
The price for the GSK plc ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.200 (-0.550%).
With 12 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 42 € there is a slightly positive potential of 16.67% for GSK plc ADR compared to the current price of 36.0 €.
So far the community has only identified positive things for GSK plc ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of GSK plc ADR in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc ADR | -0.550% | -5.263% | -13.043% | 9.756% | 7.143% | -15.789% | -19.147% |
| Astrazeneca ADR | -2.050% | -3.356% | 0.000% | 9.924% | 17.073% | 40.078% | - |
| Bayer AG ADR | -1.570% | 0.000% | -5.224% | -48.790% | -26.163% | -50.000% | -57.947% |
| Novo Nordisk A/S ADR | -2.250% | -2.909% | 6.800% | -10.101% | 42.324% | 86.453% | 190.217% |
Comments
GSK plc (NYSE: GSK) had its price target raised by analysts at Jefferies Financial Group Inc. from $52.50 to $53.00. They now have a "buy" rating on the stock.
Show more
Ratings data for GSK provided by MarketBeat
GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
GSK plc (NYSE: GSK) was upgraded by analysts at Berenberg Bank to a "strong-buy" rating.
Show more
Ratings data for GSK provided by MarketBeat